Drug Profile
Research programme: anti tau antibodies - APRINOIA Therapeutics
Latest Information Update: 31 Dec 2020
Price :
$50
*
At a glance
- Originator APRINOIA Therapeutics
- Class Antibodies; Antidementias
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 29 Dec 2020 APRINOIA Therapeutics in-licenses AI-powered system from InSilico Medicine
- 29 Jun 2020 Preclinical trials in Alzheimer's disease in Taiwan (Parenteral) before June 2020 (APRINOIA Therapeutics pipeline, June 2020)
- 29 Jun 2020 Preclinical trials in Neurodegenerative disorders in Taiwan (Parenteral) before June 2020 (APRINOIA Therapeutics pipeline, June 2020)